 Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1998 | 0 | 3 | 3 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 2 | 3 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 4 | 4 | | 2004 | 1 | 1 | 2 | | 2005 | 3 | 4 | 7 | | 2006 | 0 | 3 | 3 | | 2007 | 4 | 11 | 15 | | 2008 | 4 | 4 | 8 | | 2009 | 6 | 5 | 11 | | 2010 | 9 | 13 | 22 | | 2011 | 4 | 12 | 16 | | 2012 | 6 | 14 | 20 | | 2013 | 10 | 15 | 25 | | 2014 | 11 | 11 | 22 | | 2015 | 10 | 14 | 24 | | 2016 | 13 | 30 | 43 | | 2017 | 15 | 20 | 35 | | 2018 | 17 | 24 | 41 | | 2019 | 18 | 11 | 29 | | 2020 | 11 | 12 | 23 | | 2021 | 14 | 11 | 25 | | 2022 | 4 | 7 | 11 | | 2023 | 1 | 7 | 8 | | 2024 | 14 | 13 | 27 | | 2025 | 16 | 20 | 36 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Mar 16; 32(6):1157-1168.
-
Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, Leu JI, Duong B, Mes-Masson AM, Sims-Mourtada J, Auslander N, Drapkin R, Bitler BG, Zhang N, Murphy ME. Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. Genes Dev. 2026 02 02; 40(3-4):199-214.
-
Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A, Stebbing J, Joshi B, Bourdelais S, Delepine C, Chand D, Wu W, Johnson B, Grossman JE, O'Day SJ, Matulonis UA, Gordon MS. Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. J Immunother Cancer. 2025 Dec 23; 13(12).
-
Sessions DT, Boulton DP, Spoelstra NS, Caino MC, Yu M, Goodspeed A, Richer JK. Androgen Receptors Promote Oxidative Phosphorylation and Resistance to Palmitate Lipotoxicity in ER-Mutant Breast Cancer. Endocrinology. 2025 Dec 05; 167(1).
-
Shulman DS, Vo KT, Balis FM, Lindsay H, Bagatell R, Place AE, Chi SN, Shusterman S, Ezrre S, Czaplinski J, Bhushan K, Kao PC, London WB, DuBois SG. A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Med. 2025 Dec; 14(23):e71417.
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 Dec 01; 5(12):2112-2126.
-
Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Sci Signal. 2025 Nov 25; 18(914):eadv0415.
-
Veo B, Wang D, DeSisto J, Pierce A, Brunt B, Bompada PC, Donson A, Goodspeed A, Smart K, Foreman N, Dahl N, Vibhakar R. Single-cell multi-omics identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma. Nat Commun. 2025 Nov 25; 16(1):10470.
-
Klosowski ML, Cronise KE, Palmer EP, McAuliffe K, Stratton C, Sparks K, Malmstrom KT, Knott-Byars G, Zhou Q, Esquer H, LaBarbera DV, Regan DP. Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance. Proc Natl Acad Sci U S A. 2025 Nov 25; 122(47):e2423894122.
-
Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R. Haematologica. 2026 Apr 01; 111(4):1389-1395.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|